Visiongain: Monoclonal Antibodies in Cancer Therapy 2009-2024 on

Monoclonal antibody-based therapies for cancer are a thriving part of the biotechnology sector, as our new market report explains.
Spread the Word
Listed Under

Market Data


Cologne - North Rhine-Westphalia - Germany

Aug. 28, 2009 - PRLog -- The oncology market continues to expand worldwide, with high demand for more-efficacious and better-tolerated cancer therapies.

The monoclonal antibodies oncology market has been growing at a significant rate and holds high potential for continued growth in both developed and emerging geographical markets. Currently, new technologies are removing some of the drawbacks that monoclonal antibody therapies have experienced. Leading pharma companies are already investing heavily in monoclonal antibody technologies. Monoclonal antibodies with great commercial potential are in the oncology pipeline, as the new Visiongain report - Monoclonal Antibodies in Cancer Therapy 2009-2024 – also explains.

The period 2009 to 2019 will reveal volatility in the monoclonal antibody therapies market as current-leading products reach peak sales and new-generation drugs emerge. Will technological advances further benefit monoclonal antibody-based therapies and their overall sales? Will better immunotoxicity profiles lead to higher revenues for products? What types of monoclonal antibody therapies will enter the market from 2009 onwards, and can they dominate this market? Where will the opportunities lie, and what are the market drivers and restraints? This report gives the information that is needed to understand current trends and future possibilities. In particular, the prospects for the following products are discussed:

   * Rituxan
   * Avastin
   * Herceptin
   * Erbitux
   * Vectibix
   * Campath.

Comprehensive analysis of this important market area

Monoclonal Antibodies in Cancer Therapy 2009-2024 examines that market sector critically, through a comprehensive review of information sources, including consultations with relevant experts. This report provides detailed sales forecasts, discussions of pipeline developments and analysis of commercial drivers and restraints, including a SWOT analysis. There are over 55 tables and figures included. The result is a comprehensive market- and industry-centred report with detailed analyses and informed opinion.

Visiongain: Monoclonal Antibodies in Cancer Therapy 2009-2024:

Visiongain: More market data and market reports:

# # #, founded in 2002 has emerged as a leading online portal for market surveys and market research in German speaking areas. Four years later the English language portal was introduced due to the extraordinary success of the portal. Again one year later - the Spanish spoken portal - was founded. The objective of the three portals is to competently and efficiently support consultants and decision makers in management, sales and marketing in the search for worldwide market research. Prospective buyers can look into more than 60,000 market.
Email:*** Email Verified
Phone:++49 (0)221 690 688 55
Tags:Cancer, Antibody, Monoclonal, Biotechnology, Therapies, Market Data, Pharma
Industry:Health, Medical
Location:Cologne - North Rhine-Westphalia - Germany
Account Email Address Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share